Vaccines News and Research RSS Feed - Vaccines News and Research

Flu vaccines have protective effect against heart disease

Flu vaccines have protective effect against heart disease

Flu vaccines are known to have a protective effect against heart disease, reducing the risk of a heart attack. For the first time, this research, published in Vaccine, reveals the molecular mechanism that underpins this phenomenon. The scientists behind the study say it could be harnessed to prevent heart disease directly. [More]
Two IOM members honored for outstanding service

Two IOM members honored for outstanding service

The Institute of Medicine honored members Dan G. Blazer and Richard B. Johnston Jr. for their outstanding service during the IOM's 44th annual meeting in Washington, D.C. [More]
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. [More]
Ebola Virus and Public Health: A special feature by Disaster Medicine and Public Health

Ebola Virus and Public Health: A special feature by Disaster Medicine and Public Health

Accurate knowledge regarding Ebola is critical and pertinent for practicing physicians and clinicians given the current risk of hazardous global outbreak and epidemic. [More]
TSRI scientists identify long-sought activating molecules for subset of immune system cells

TSRI scientists identify long-sought activating molecules for subset of immune system cells

Scientists at The Scripps Research Institute (TSRI) have identified the long-sought activating molecules for a rare but crucial subset of immune system cells that help rally other white blood cells to fight infection. [More]
Scientists develop promising vaccination strategy to counteract RSV infection

Scientists develop promising vaccination strategy to counteract RSV infection

Respiratory Syncytial Virus causes severe respiratory tract infections and worldwide claims the lives of 160,000 children each year. Scientists at VIB and Ghent University have succeeded in developing a promising vaccination strategy to counteract this common virus infection. [More]
NIAID announces license agreement to develop dual-purpose candidate vaccines for rabies, Ebola

NIAID announces license agreement to develop dual-purpose candidate vaccines for rabies, Ebola

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced a new license agreement aimed at advancing dual-purpose candidate vaccines to protect against rabies and Ebola viruses. [More]
Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer. [More]
Myths, misconceptions about seasonal flu and flu vaccine

Myths, misconceptions about seasonal flu and flu vaccine

It's that time of year again. As days shorten, evenings become chilly and the trees start a showy display of color, it's time to roll up your sleeve and get your annual flu vaccine. [More]
Kalorama Information: Experimental vaccine distribution in the UK points to growing flu vaccine market

Kalorama Information: Experimental vaccine distribution in the UK points to growing flu vaccine market

Kalorama Information believes an experimental vaccine distribution in the United Kingdom and other similar developments point to a growing flu vaccine market, as well as a growing market for the production of these vaccines. [More]
Foreign-born residents with low vaccination rates face greater risk of exposure to diseases

Foreign-born residents with low vaccination rates face greater risk of exposure to diseases

Foreign-born residents with low vaccination rates and their relatives in the U.S. are at greater risk of exposure to several vaccine-preventable diseases, e.g. influenza; pneumococcal diseases; tetanus, diphtheria and pertussis; hepatitis A; hepatitis B; shingles; and HPV, the human papilloma virus, which can lead to some types of cancer. [More]
Statement on Ebola epidemic

Statement on Ebola epidemic

The Ebola virus is spreading rapidly and to an unexpected extent. The outbreak does not follow the patterns experienced in the past and the virus shows a new disease dynamic in regions, where it has never been recorded before. For this reason, the German National Academy of Sciences Leopoldina, acatech – the German Academy of Science and Engineering, and the Union of the German Academies of Sciences and Humanities have presented a statement on the Ebola epidemic today. [More]
MGH, MIT partner to accelerate development of diagnostic tools and therapies

MGH, MIT partner to accelerate development of diagnostic tools and therapies

A novel partnership between Massachusetts General Hospital and Massachusetts Institute of Technology is addressing three major challenges in clinical medicine – improving the diagnosis of disease, developing new approaches to prevent and treat infectious and autoimmune diseases, and developing more accurate methods of diagnosing and treating major neurodegenerative and psychiatric diseases. While individual collaborations between MGH and MIT investigators are nothing new, this formalized strategic partnership is designed to accelerate the development of diagnostic tools and therapies. [More]
Promising vaccination strategy to counteract RSV

Promising vaccination strategy to counteract RSV

Respiratory Syncytial Virus causes severe respiratory tract infections and worldwide claims the lives of 160,000 children each year. Scientists at VIB and Ghent University have succeeded in developing a promising vaccination strategy to counteract this common virus infection. [More]
Columbia University professor recommends vaccination for people travelling abroad

Columbia University professor recommends vaccination for people travelling abroad

Planning to travel outside the U.S. this holiday season? Check with your primary care provider or travel clinic when you book your flight. [More]
Four out of ten children in Burkina Faso genetically resistant to virus strains

Four out of ten children in Burkina Faso genetically resistant to virus strains

Every year rotavirus causes half a million diarrhoea-related deaths amongst children in developing countries. Existing vaccines provide poor protection. The reason could be a widespread genetic resistance amongst children, according to virologists at Linköping University. [More]
Imaxio, DKFZ partner to evaluate potential of IMX313 with candidate vaccine targeting HPV

Imaxio, DKFZ partner to evaluate potential of IMX313 with candidate vaccine targeting HPV

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has signed an option for a license agreement with the world-renowned German Center for Cancer Research (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed. [More]
First study of promising Ebola vaccine commenced in West Africa

First study of promising Ebola vaccine commenced in West Africa

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development at the University of Maryland School of Medicine, and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced today that the CVD, in conjunction with its sister institution, The Center for Vaccine Development of Mali and the Ministry of Health of Mali, have begun a clinical trial in health care workers (and other front-line workers) to evaluate a promising experimental Ebola vaccine. [More]
NanoBio to highlight prophylactic NE HSV-2 vaccine candidate at The Keystone Symposia Conference

NanoBio to highlight prophylactic NE HSV-2 vaccine candidate at The Keystone Symposia Conference

NanoBio Corporation today announced that the company will present data at The Keystone Symposia Conference, The Modes of Action of Vaccine Adjuvants, in Seattle on October 12, 2014. [More]